Health & Fitness
Thu, April 12, 2012Wed, April 11, 2012Tue, April 10, 2012Mon, April 9, 2012Fri, April 6, 2012Thu, April 5, 2012Wed, April 4, 2012Tue, April 3, 2012Mon, April 2, 2012Sun, April 1, 2012Sat, March 31, 2012Fri, March 30, 2012Thu, March 29, 2012Wed, March 28, 2012Savient Pharmaceuticals to Present at the Imperial Capital Healthcare Investor Forum
//health-fitness.news-articles.net/content/2012/ .. -imperial-capital-healthcare-investor-forum.html
Published in Health and Fitness on Tuesday, April 3rd 2012 at 13:15 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
Savient Pharmaceuticals to Present at the Imperial Capital Healthcare Investor Forum -- EAST BRUNSWICK, N.J., April 3, 2012 /PRNewswire/ --
Savient Pharmaceuticals to Present at the Imperial Capital Healthcare Investor Forum
EAST BRUNSWICK, N.J., April 3, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: [ SVNT ]) today announced that Lou Ferrari, Executive Vice President and President North American Commercial Operations, will present at the Imperial Capital Healthcare Investor Forum on Tuesday, April 17th, 2012 at 11:30 AM Eastern Time. The conference will be held at the New York Palace Hotel, New York, NY.
A live webcast of the presentation can be accessed through the investor relations section of the Company's website at [ www.savient.com ]. Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at [ www.savient.com ].
Contact: | |
Mary Coleman | Carney Noensie |
Savient Pharmaceuticals, Inc. | Burns McClellan |
(732) 418-9300 | (212) 213-0006 |
SVNT – G
SOURCE Savient Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.savient.com ]
